Clostridium difficile rates in stem cell transplant patients are approximately 9 times greater than in hospitalized patients, with rates about twice as high in allogeneic vs autologous transplants.
Liza Vaezi, MSc, Pharm D, DPLA, BCPS-AQ ID
Advertisement
Articles by Liza Vaezi, MSc, Pharm D, DPLA, BCPS-AQ ID
Advertisement
Latest Updated Articles
Can Fidaxomicin Provide Effective C difficile-Associated Diarrhea Prophylaxis for HSCT Recipients?Published: March 18th 2019 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Developing a COVID-19 Vaccine Alternative
2
Generic Lenacapavir Could Cost as Little as $25 Per Person Annually
3
Building Trust Through Vaccine Education and Science Communication
4
Real-World Data Reinforce Effectiveness and Safety of Fecal Microbiota Therapy for Preventing Recurrent C difficile
5
